KRAS and lung adenocarcinoma: For instance, Nguyen and associates [29] analyzed six pathway-specific gene expression signatures (TGFβ, KRAS, TCF4, SRC, E2F3, and MYC) in cohorts of lung adenocarcinomas and primary breast tumors for which the MFS status was available, and identified signatures that can predict breast cancer recurrence (TGFβ signature) and lung cancer recurrence (TCF4 and MYC signatures).